Alzheimer’s Disease | Disease Landscape & Forecast | G7 | 2023

The landmark FDA approval of Biogen / Eisai’s aducanumab (Aduhelm) in 2021 has had a minimal effect on treatment dynamics in AD owing to the lack of reimbursement and the controversy surrounding its approval. Eisai / Biogen’s lecanemab (Leqembi) achieved accelerated and traditional FDA approvals, as well as MHLW approval, in 2023; an application for traditional approval in Europe has been accepted by regulators and additional filings for maintenance IV dosing and SC delivery are expected. Other DMTs will soon follow in the United States and other markets (e.g., Eli Lilly’s donanemab), seeking to fulfill the potential for a DMT in the AD market. Meanwhile, in May 2023, Lundbeck / Otsuka’s Rexulti became the first therapy to receive FDA approval for AD agitation, and additional therapies are expected to reach market for AD agitation (e.g., Otsuka’s AVP-786, Axsome’s Auvelity) and AD psychosis (i.e., Karuna Therapeutics’ KarXT). The launch of these potential blockbusters could meaningfully alter the dynamics of this market, driven by clear need, strong market demand, and premium pricing.

QUESTIONS ANSWERED

• How large is the treatable AD population? What will be the impact of future anti-Aβ MAbs on diagnosis / drug treatment rates if these agents become available and accessible for early AD?
• What are KOLs’ opinions of recently launched therapies (e.g., Corium’s Adlarity) and other key symptomatic and disease-modifying therapies in development for AD?
• What commercial uptake can Rexulti, AVP -786, and Auvelity (AXS-05) expect if they launch for AD agitation?
• What are the drivers and constrainers of the AD therapy market, and how might they change over the forecast period as premium-priced agents launch?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.